Journal of Medicinal Chemistry · 2010 · 34 citations · 28 references
Organic ChemistryPharmacotherapyChemistryChemical DerivativePharmaceutical ChemistryTumor BiologyMedicinal ChemistryIlludin SAnti-cancer AgentRadiation OncologyDerivativesLead AcylfulveneDrug DevelopmentSulfonamide DerivativesPharmacologyNatural SciencesMedicineDerivative (Chemistry)Synthetic ChemistryDrug Discovery
Illudin S and M (1, 2) are highly toxic sesquiterpenes found in the basidiomycete Omphalotus illudens. Illudins have a low therapeutic index, but acylfulvene derivatives display potent in vivo antitumor activity against a variety of multidrug resistant tumors. The lead acylfulvene (4), irofulven (5), in a randomized phase IIB clinical trial significantly increased overall survival in patients with metastatic hormone-refractory prostate cancer who failed prior treatment with two different standard chemotherapeutic regimens. Irofulven is unique, as the primary allylic hydroxyl group can undergo displacement with a variety of nucleophiles to produce analogues that retain key functional groups required for biological activity including the reactive cyclopropylmethyl carbinol and alpha,beta-unsaturated ketone. As described here, we synthesized a variety of urea, carbamate, and sulfonamide derivatives that retain key functional groups and display potent biological activity toward target solid tumor cells in vitro but are relatively nontoxic toward a nontarget B-cell derived cell line.
28
Giuseppina De Simone, Anna Di Fiore, Valeria Menchise et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 185 citations · Full text
Molecular Pharmacology, Medicinal Chemistry, Biochemistry +11
Jean‐Yves Winum, Daniela Vullo, Angela Casini et al. · Journal of Medicinal Chemistry · 2003 · 128 citations · Full text
Preclinical evaluation of illudins as anticancer agents.
Michael J. Kelner, Trevor C. McMorris, William T. Beck et al. · PubMed · 1987 · 117 citations